Fast biomarker screening of pancreatic cancer clinical trials using AlGaN/GaN high electron mobility transistors

Sheng-Ting Hung^1*

¹Department of Physics, National Sun Yat-sen University, Kaohsiung, Taiwan

* Presenter:Sheng-Ting Hung, email:sth@mail.nsysu.edu.tw

Cancer is the second and the first leading cause of death in the United States and Taiwan, respectively. Pancreatic cancer remains a highly fatal disease with a 5-year relative survival rate of only 13% between 2013 and 2019. Developing reliable early detection methods, including detection tool development and target biomarker selection, is the key to reducing the fatality rate of pancreatic cancer. AlGaN/GaN high electron mobility transistor (HEMT) is a promising platform for detecting rare clinical biomarkers due to their high sensitivity, high electron mobility, and high efficiency characteristics. We have developed an antibody-functionalized AlGaN/GaN HEMT biosensing chip using the self-assembled monolayer (SAM) technique for rapid detection of biomarkers. We demonstrated the potential of this HEMT biosensor in clinical applications by carrying out clinical trials screening pancreatic cancer biomarkers CA19-9 and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant protein KRAS G12D.

Keywords: AlGaN/GaN high electron mobility transistor biosensor, Self-assembled monolayer, Pancreatic cancer , KRAS G12D, CA19-9